Frequenty Asked Questions
Platform Technology & Scientific Architecture
Cardiotoxicity & Translational Pharmacology
Disease Modelling & Therapeutic Development
Regulatory Integration & NAM Alignment
Commercial, Collaboration & Strategic Considerations
Platform Technology & Scientific Architecture
1. What is TrueCardium®?
TrueCardium® is a human cardiac New Approach Methodology (NAM) platform comprising vascularised, innervated, multicellular three-dimensional human cardiac organoids designed for translational drug development, disease modelling, and cardiotoxicity assessment.
Unlike reductionist 2D assays, TrueCardium® models integrated tissue-level cardiac biology, incorporating cardiomyocytes, endothelial cells, mural cells, fibroblasts, neuronal elements, and immune components within a spatially organised architecture.
2. How does TrueCardium® differ from conventional cardiac in vitro assays?
Traditional in vitro cardiac assays often rely on isolated cardiomyocytes or 2D monolayer cultures. While useful for specific electrophysiological screening applications, these systems lack multicellular architecture and heterocellular signalling networks.
TrueCardium® organoids replicate tissue-level organisation and cellular cross-talk, enabling assessment of contractility, electrophysiology, vascular interactions, inflammatory modulation, and metabolic coupling within a human-relevant three-dimensional context.
3. Which cardiac cell types are included in the platform?
TrueCardium® integrates:
- Cardiomyocytes (working myocardium)
- Endothelial cells
- Pericytes and smooth muscle cells (mural populations)
- Fibroblasts and stromal cells
- Neurons
- Resident immune components
This multicellular composition supports modelling of vascular, neuro-cardiac, inflammatory, and stromal interactions relevant to adult human myocardium.
4. Why is multicellularity important in cardiac drug development?
Cardiac pharmacologic responses emerge from coordinated interactions between multiple cellular compartments. Isolated cardiomyocyte systems may capture ion channel effects but cannot fully model vascular signalling, inflammatory modulation, metabolic adaptation, or neuro-cardiac regulation.
Multicellular architecture improves translational interpretability by enabling integrated tissue-level responses.
5. What functional readouts are available?
TrueCardium® supports:
- Contractility measurements
- Electrophysiological analysis
- Calcium handling dynamics
- Viability and cytotoxicity metrics
- Transcriptomic and proteomic profiling
- Pathway-level mechanistic interrogation
- Vascular and inflammatory response markers
Functional outputs can be aligned with defined nonclinical safety or efficacy questions.
6. Are the organoids vascularised?
Yes. The platform incorporates endothelial and mural components enabling vascular network formation and paracrine signalling consistent with human cardiac microvasculature.
This supports modelling of angiogenic, inflammatory, and vascular-mediated drug responses.
7. Are the organoids innervated?
TrueCardium® incorporates neuronal elements enabling modelling of neuro-cardiac cross-talk, autonomic signalling influences, and electrophysiological modulation relevant to arrhythmogenic risk and stress responses.
8. What is the maturation state of the organoids?
The platform is engineered to reflect adult-like cardiac architecture and functional phenotypes relative to defined context-of-use. Maturation parameters are benchmarked using structural, molecular, and electrophysiological metrics.
9. How reproducible is the platform?
Genome Biologics applies defined SOPs, quality control metrics, and batch validation processes to ensure:
- Intra-run reproducibility
- Inter-run consistency
- Structural and functional stability
Reproducibility is critical for regulatory-facing nonclinical applications.
10. Can the platform be customized?
Yes. Disease-specific models, genetic backgrounds, exposure paradigms, and pharmacologic interventions can be integrated depending on the translational objective.
Cardiotoxicity & Translational Pharmacology
1. Can TrueCardium® predict cardiotoxicity?
TrueCardium® enables detection of contractile dysfunction, electrophysiologic instability, inflammatory injury, and metabolic stress under pharmacologic exposure.
2. Does the platform address QT-related liability?
Electrophysiologic profiling supports assessment relevant to pro-arrhythmic risk paradigms, complementing existing hERG and CiPA-aligned strategies.
3. Can False Negatives from reductionist systems be reduced?
Multicellular integration allows detection of toxicities mediated through endothelial dysfunction, inflammatory signaling, or heterocellular coupling not observable in isolated cardiomyocyte assays.
4. Is TrueCardium® compatible with CiPA frameworks?
The platform can complement Comprehensive in vitro Proarrhythmia Assay (CiPA) strategies by adding tissue-level context.
5. Can exposure–response relationships be quantified?
Yes. Pharmacologic dosing paradigms can be structured to evaluate exposure-response relationships relevant to translational decision-making.
6. Is chronic cardiotoxicity assessable?
Yes. Extended exposure paradigms allow modeling of delayed or progressive cardiac injury.
7. Can oncology compounds be evaluated?
Yes. The platform is suitable for assessment of kinase inhibitors, antibody-drug conjugates, and other targeted agents for cardiac liability.
8. Does the system capture vascular-mediated toxicity?
The platform is engineered to reflect adult-like cardiac architecture and functional phenotypes relative to defined context-of-use. Maturation parameters are benchmarked using structural, molecular, and electrophysiological metrics.
9. Can contractility modulation be quantified?
Force and beat-rate analyses support evaluation of positive and negative inotropic effects.
10. Is the platform suited for early de-risking?
Yes. TrueCardium® can be deployed in lead optimization, candidate selection, and integrated nonclinical packages.
Disease Modelling & Therapeutic Development
1. What disease models are available?
TrueCardium® supports modelling of:
- Heart failure with preserved ejection fraction (HFpEF)
- Heart failure with reduced ejection fraction (HFrEF)
- Hypertrophic remodeling
- Cardiac fibrosis
- Inflammatory cardiomyopathies
- Mitochondrial cardiomyopathies
- Clonal hematopoiesis-related cardiac dysfunction
- Hypertrophy and remodelling
- Viral cardiotoxicity
- Age-related dysfunction
- Congenital cardiac disorders
2. How does the HFpEF model differ from standard cardiomyocyte assays?
HFpEF is a multicellular, inflammatory, microvascular disease. TrueCardium® enables modelling of endothelial dysfunction, stromal activation, inflammatory signalling, and cardiomyocyte stiffness within an integrated tissue context.
3. Can TrueCardium® be used for RNA-based therapeutics?
Yes. The platform has been used to evaluate miRNA modulation strategies and other nucleic acid-based therapeutics within structurally organised human cardiac tissue.
4. How does the platform support target validation?
Integrated readouts allow correlation between molecular perturbation and functional tissue phenotype, enabling target de-risking prior to clinical entry.
5. Can mitochondrial disease be modelled?
Yes. Vascularised organoids enable assessment of metabolic dysfunction, oxidative stress, and mitochondrial–cell cycle interactions in human cardiac tissue.
6. Is the platform suitable for inflammatory cardiology research?
Yes. Inclusion of stromal and immune components enables modelling of inflammatory modulation and cytokine-driven cardiac dysfunction.
7. Can the platform model viral cardiotoxicity?
Human cardiac organoids have been used to assess SARS-CoV-2 infection and variant-specific cytotoxicity, demonstrating applicability in infectious cardiology contexts.
8. How does the platform support hypertrophy modelling?
Pressure-mimetic and molecular hypertrophy paradigms can be integrated with transcriptomic and functional readouts.
9. Can TrueCardium® model complex comorbid conditions?
Yes. The multicellular architecture allows integration of inflammatory, metabolic, and vascular components, enabling modeling of multifactorial pathologies such as cardioinflammatory syndromes.
10. Can exposure–response relationships be evaluated?
Yes. Defined dosing paradigms allow integration of pharmacokinetic modelling with tissue-level pharmacodynamic readouts.
11. Is TrueCardium® intended to replace animal models?
No. The platform is designed to complement existing nonclinical strategies by providing human-relevant data that may enhance translational interpretability.
Regulatory Integration & NAM Alignment
1. Is TrueCardium® considered a New Approach Methodology (NAM)?
Yes. The platform aligns with regulatory definitions of human-relevant, non-animal methodologies designed to inform nonclinical development.
2. Has the platform been reviewed in regulatory contexts?
TrueCardium® data has been reviewed in regulatory interactions including German BfArM and U.S. FDA contexts as part of integrated nonclinical packages.
3. How does the platform align with FDA ISTAND principles?
TrueCardium® supports context-of-use definition, mechanistic interpretability, reproducibility, and defined performance characteristics consistent with ISTAND evaluation domains.
4. Is the platform compatible with CiPA-aligned paradigms?
Electrophysiological and mechanistic outputs can complement CiPA-aligned proarrhythmia assessment frameworks.
5. Can data support IND-enabling packages?
TrueCardium® data may be incorporated within broader nonclinical pharmacology and safety packages depending on context-of-use and regulatory strategy.
6. What validation data is available?
Validation includes structural characterisation, functional benchmarking, reference compound testing, and reproducibility documentation.
7. How does regulatory integration occur?
Integration depends on defined context-of-use, exposure paradigms, and structured documentation aligned to existing nonclinical review frameworks.
8. Does the platform reduce translational risk?
By generating human-relevant tissue-level data, the platform may improve mechanistic clarity and early de-risking of candidate compounds.
9. Is it suitable for regulatory dialogue prior to Phase I?
Yes, particularly when aligned to defined decision questions and integrated within broader pharmacology strategies.
10. Does Genome Biologics engage in regulatory consultation?
Genome Biologics collaborates with partners to define context-of-use and documentation standards appropriate for regulatory engagement.
Commercial, Collaboration & Strategic Considerations
1. Who are typical partners?
Pharmaceutical companies, biotechnology firms, venture-backed therapeutics developers, and academic translational programs.
2. What stages of development are supported?
Discovery
Lead optimisation
Preclinical validation
IND-enabling strategy support
3. Can projects be structured as CRO engagements?
Yes. Genome Biologics provides end-to-end cardiac safety pharmacology and disease-model screening services.
4. Are collaborative research models available?
Yes. Co-development, grant collaboration, and strategic research partnerships are supported.
5. What is the turnaround time?
Timelines depend on project scope, disease model complexity, and exposure paradigms.
6. Is IP ownership preserved?
Project-specific agreements define IP ownership, data rights, and confidentiality.
7. Can high-throughput screening be performed?
Platform configurations can be adapted depending on screening scale requirements.
8. Is the platform scalable?
Production workflows are designed to enable structured scalability while maintaining reproducibility.
9. How does Genome Biologics differentiate itself?
The platform emphasises multicellular architectural fidelity, vascular integration, and translational interpretability aligned to regulatory-facing development strategies.
10. Where can further technical details be found?
Detailed evaluation criteria and regulatory context-of-use considerations are available at: www.cardiacnam.com